Elaine Mary Shannon Sells 3,978 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Elaine Mary Shannon sold 3,978 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $68,023.80. Following the transaction, the insider owned 63,333 shares of the company’s stock, valued at approximately $1,082,994.30. The trade was a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.06 on Wednesday, hitting $17.42. 2,004,364 shares of the company were exchanged, compared to its average volume of 4,402,927. The company’s 50 day moving average price is $16.49 and its two-hundred day moving average price is $17.13. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $6.90 billion during the quarter. Research analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TAK. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TAK. Royal Bank of Canada boosted its stake in shares of Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after purchasing an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Focus Partners Wealth lifted its holdings in Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after purchasing an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in Takeda Pharmaceutical in the second quarter valued at about $351,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.